Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort studyResearch in context

• Egile Nagusiak: Katherine Adams (Egilea), John J. Riddles (Egilea), Elizabeth A.K. Rowley (Egilea), Shaun J. Grannis (Egilea), Manjusha Gaglani (Egilea), Bruce Fireman (Egilea), Emily Hartmann (Egilea), Allison L. Naleway (Egilea), Edward Stenehjem (Egilea), Alexandria Hughes (Egilea), Alexandra F. Dalton (Egilea), Karthik Natarajan (Egilea), Kristin Dascomb (Egilea), Chandni Raiyani (Egilea), Stephanie A. Irving (Egilea), Chantel Sloan-Aagard (Egilea), Anupam B. Kharbanda (Egilea), Malini B. DeSilva (Egilea), Brian E. Dixon (Egilea), Toan C. Ong (Egilea), Jean Keller (Egilea), Monica Dickerson (Egilea), Nancy Grisel (Egilea), Kempapura Murthy (Egilea), Juan Nanez (Egilea), William F. Fadel (Egilea), Sarah W. Ball (Egilea), Palak Patel (Egilea), Julie Arndorfer (Egilea), Mufaddal Mamawala (Egilea), Nimish R. Valvi (Egilea), Margaret M. Dunne (Egilea), Eric P. Griggs (Egilea), Peter J. Embi (Egilea), Mark G. Thompson (Egilea), Ruth Link-Gelles (Egilea), Mark W. Tenforde (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2023-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Summary: Background: Understanding the usefulness of additional COVID-19 vaccine doses-particularly given varying disease incidence-is needed to support public health policy. We characterize the benefits of COVID-19 booster doses using number needed to vaccinate (NNV) to prevent one COVID-19-associa...